Changsheng Bio Delisted following Major Vaccine Scandal
publication date: Oct 9, 2019
Changsheng Biotechnology, a Jilin vaccine biotech, will be delisted from the Shenzhen Stock Exchange one year after the company was discovered to be selling substandard vaccines. Investigators found that Changsheng Bio fabricated records for an inspection and that its DPT (diphtheria, pertussis, and tetanus) vaccine for children was largely ineffective. China has declared war on drug/vaccine companies that sell substandard products -- regulators want to build confidence in domestic drug products -- and the delisting shows the country's resolve. More details....
Stock Symbol: (SHZ: 002680)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.